These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 16783197

  • 1. Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis.
    Gomes RN, Bozza FA, Amâncio RT, Japiassú AM, Vianna RC, Larangeira AP, Gouvêa JM, Bastos MS, Zimmerman GA, Stafforini DM, Prescott SM, Bozza PT, Castro-Faria-Neto HC.
    Shock; 2006 Jul; 26(1):41-9. PubMed ID: 16783197
    [Abstract] [Full Text] [Related]

  • 2. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
    Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J, Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators.
    Crit Care Med; 2004 Feb; 32(2):332-41. PubMed ID: 14758145
    [Abstract] [Full Text] [Related]

  • 3. Bacterial clearance is improved in septic mice by platelet-activating factor-acetylhydrolase (PAF-AH) administration.
    Teixeira-da-Cunha MG, Gomes RN, Roehrs N, Bozza FA, Prescott SM, Stafforini D, Zimmerman GA, Bozza PT, Castro-Faria-Neto HC.
    PLoS One; 2013 Feb; 8(9):e74567. PubMed ID: 24069320
    [Abstract] [Full Text] [Related]

  • 4. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.
    Schuster DP, Metzler M, Opal S, Lowry S, Balk R, Abraham E, Levy H, Slotman G, Coyne E, Souza S, Pribble J, Pafase ARDS Prevention Study Group.
    Crit Care Med; 2003 Jun; 31(6):1612-9. PubMed ID: 12794395
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis.
    Sherman S, Alazmi WM, Lehman GA, Geenen JE, Chuttani R, Kozarek RA, Welch WD, Souza S, Pribble J, rPAF-AH ERCP Study Group.
    Gastrointest Endosc; 2009 Mar; 69(3 Pt 1):462-72. PubMed ID: 19231487
    [Abstract] [Full Text] [Related]

  • 6. The role of recombinant platelet-activating factor acetylhydrolase in a neonatal rat model of necrotizing enterocolitis.
    Caplan MS, Lickerman M, Adler L, Dietsch GN, Yu A.
    Pediatr Res; 1997 Dec; 42(6):779-83. PubMed ID: 9396557
    [Abstract] [Full Text] [Related]

  • 7. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin.
    Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD.
    Nephrol Dial Transplant; 2006 May; 21(5):1270-7. PubMed ID: 16421163
    [Abstract] [Full Text] [Related]

  • 8. Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection.
    Caini P, Guerra CT, Giannini C, Giannelli F, Gragnani L, Petrarca A, Solazzo V, Monti M, Laffi G, Zignego AL.
    J Viral Hepat; 2007 Jan; 14(1):22-8. PubMed ID: 17212640
    [Abstract] [Full Text] [Related]

  • 9. Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice.
    Singh U, Zhong S, Xiong M, Li TB, Sniderman A, Teng BB.
    Clin Sci (Lond); 2004 Apr; 106(4):421-32. PubMed ID: 14717654
    [Abstract] [Full Text] [Related]

  • 10. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress.
    Noto H, Hara M, Karasawa K, Iso-O N, Satoh H, Togo M, Hashimoto Y, Yamada Y, Kosaka T, Kawamura M, Kimura S, Tsukamoto K.
    Arterioscler Thromb Vasc Biol; 2003 May 01; 23(5):829-35. PubMed ID: 12649088
    [Abstract] [Full Text] [Related]

  • 11. The proangiogenic phenotype of tumor-derived endothelial cells is reverted by the overexpression of platelet-activating factor acetylhydrolase.
    Doublier S, Ceretto M, Lupia E, Bravo S, Bussolati B, Camussi G.
    Clin Cancer Res; 2007 Oct 01; 13(19):5710-8. PubMed ID: 17908960
    [Abstract] [Full Text] [Related]

  • 12. Effect of recombinant platelet-activating factor acetylhydrolase on two models of experimental acute pancreatitis.
    Hofbauer B, Saluja AK, Bhatia M, Frossard JL, Lee HS, Bhagat L, Steer ML.
    Gastroenterology; 1998 Nov 01; 115(5):1238-47. PubMed ID: 9797380
    [Abstract] [Full Text] [Related]

  • 13. Neuroprotection by platelet-activating factor acetylhydrolase in a mouse model of transient cerebral ischemia.
    Wu Y, Wang L, Dai C, Ma G, Zhang Y, Zhang X, Wu Z.
    Neurosci Lett; 2014 Jan 13; 558():26-30. PubMed ID: 24189491
    [Abstract] [Full Text] [Related]

  • 14. The impact of platelet-activating factor (PAF)-like mediators on the functional activity of neutrophils: anti-inflammatory effects of human PAF-acetylhydrolase.
    Kuijpers TW, van den Berg JM, Tool AT, Roos D.
    Clin Exp Immunol; 2001 Mar 13; 123(3):412-20. PubMed ID: 11298128
    [Abstract] [Full Text] [Related]

  • 15. Inter-individual variability of plasma PAF-acetylhydrolase activity in ARDS patients and PAFAH genotype.
    Li S, Stuart L, Zhang Y, Meduri GU, Umberger R, Yates CR.
    J Clin Pharm Ther; 2009 Aug 13; 34(4):447-55. PubMed ID: 19583678
    [Abstract] [Full Text] [Related]

  • 16. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease.
    Ninio E, Tregouet D, Carrier JL, Stengel D, Bickel C, Perret C, Rupprecht HJ, Cambien F, Blankenberg S, Tiret L.
    Hum Mol Genet; 2004 Jul 01; 13(13):1341-51. PubMed ID: 15115767
    [Abstract] [Full Text] [Related]

  • 17. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase.
    Tsironis LD, Mitsios JV, Milionis HJ, Elisaf M, Tselepis AD.
    Cardiovasc Res; 2004 Jul 01; 63(1):130-8. PubMed ID: 15194469
    [Abstract] [Full Text] [Related]

  • 18. [Plasma platelet-activating factor acetylhydrolase (PAF-AH) deficiency as a risk factor for stroke].
    Satoh K.
    Brain Nerve; 2008 Nov 01; 60(11):1319-24. PubMed ID: 19069165
    [Abstract] [Full Text] [Related]

  • 19. Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth.
    Biancone L, Cantaluppi V, Del Sorbo L, Russo S, Tjoelker LW, Camussi G.
    Clin Cancer Res; 2003 Sep 15; 9(11):4214-20. PubMed ID: 14519648
    [Abstract] [Full Text] [Related]

  • 20. Lung production of platelet-activating factor acetylhydrolase in oleic acid-induced acute lung injury.
    Salluh JI, Pino AV, Silva AR, Gomes RN, Souza HS, e Silva JR, Jandre FC, Giannella-Neto A, Zimmerman GA, Stafforini DM, Prescott SM, Castro-Faria-Neto HC, Bozza PT, Bozza FA.
    Prostaglandins Leukot Essent Fatty Acids; 2007 Jul 15; 77(1):1-8. PubMed ID: 17629689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.